Soluble Fas affects erythropoiesis in vitro and acts as potential predictor of erythropoiesis-stimulating agents therapy in chronic kidney disease patients.

Soluble Fas affects erythropoiesis in vitro and acts as potential predictor of erythropoiesis-stimulating agents therapy in chronic kidney disease patients. Am J Physiol Renal Physiol. 2020 Jan 31;: Authors: Chiloff DM, de Almeida DC, Dalboni MA, Canziani MEF, George SK, Morsi AM, El-Akabawy N, Porada CD, Durao MS, Zarjou A, Almeida-Porada G, Goes MA Abstract Serum soluble Fas levels (sFas) is associated to erythropoietin (Epo) hyporesponsiveness in patients with chronic kidney disease (CKD). If sFas could predict the need for erythropoiesis-stimulating agents (ESA) usage and influence in erythropoiesis remains unclear. We evaluated the relation between sFas and ESA therapy in CKD patients with anemia and its effect on erythropoiesis in vitro. First, we performed a retrospective cohort study with 77 anemic patients with non-dialysis CKD. We performed in vitro studies to investigate whether sFas could interfere with the behavior of hematopoietic stem cells (HSC). HSC were isolated from umbilical cord blood and incubated with recombinant sFas protein in a dose-dependent manner. Serum sFas positively correlated with Epo levels (r=0.30, p=0.001) but negatively with Hgb (r=-0.55, p<0.001) and eGFR (r=-0.58, p<0.001) in CKD patients at baseline. Elevated sFas serum levels (4,316±897 vs 2,776±749; p<0.001) with lower eGFR (26.2±10.1 vs 33.5±14.3; p=0.01) and reduced Hgb concentration (11.1±0.9 vs 12.5±1.2; p<0.001) were id...
Source: American Journal of Physiology. Renal Physiology - Category: Physiology Authors: Tags: Am J Physiol Renal Physiol Source Type: research